The estimated Net Worth of Jack A. Khattar is at least $37.2 Milion dollars as of 3 September 2024. Mr. Khattar owns over 21,000 units of Supernus Pharmaceuticals Inc stock worth over $29,097,624 and over the last 13 years he sold SUPN stock worth over $0. In addition, he makes $8,123,130 as President, Chief Executive Officer, Secretary oraz Director at Supernus Pharmaceuticals Inc.
Sign up
Mr. Khattar SUPN stock SEC Form 4 insiders trading
Jack has made over 26 trades of the Supernus Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 21,000 units of SUPN stock worth $652,680 on 3 September 2024.
The largest trade he's ever made was exercising 192,000 units of Supernus Pharmaceuticals Inc stock on 8 August 2022 worth over $5,967,360. On average, Jack trades about 10,038 units every 62 days since 2012. As of 3 September 2024 he still owns at least 936,217 units of Supernus Pharmaceuticals Inc stock.
You can see the complete history of Mr. Khattar stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jack Khattar biography
Jack A. Khattar serves as President, Chief Executive Officer, Secretary, Director of the Company. He is the founder of our Company and has served as our President, Chief Executive Officer and Secretary and a Director since 2005. From 1999 to 2005, Mr. Khattar served in various positions during that time as a board member, President and Chief Executive Officer of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. From 1999 to 2004, he also served as a member of Shire plc's executive committee. Prior to that, Mr. Khattar served as an executive officer and the chairman of the management committee at CIMA Labs Inc. (CIMA), a drug delivery company where he was also responsible for business development, corporate alliances and strategic planning. Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis, Playtex and Kodak in various locations, including the United States, Europe and the Middle East. Mr. Khattar served on the board of Rockville Economic Development, Inc. from 2003 until 2013. He currently serves on the board of directors of Prevacus, Inc., a privately-held development stage biotechnology company, and on the advisory board of New Rhein Healthcare, a private equity firm. Mr. Khattar also serves as Chairman of the board of directors of scPharmaceuticals, a publicly traded pharmaceutical company. Mr. Khattar earned his degrees in Marketing with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania. Mr. Khattar's leadership, executive, managerial, business and pharmaceutical company experience, along with his more than 30 years of industry experience in the development and commercialization of pharmaceutical products and drug delivery technologies, qualify him to be a director.
What is the salary of Jack Khattar?
As the President, Chief Executive Officer, Secretary oraz Director of Supernus Pharmaceuticals Inc, the total compensation of Jack Khattar at Supernus Pharmaceuticals Inc is $8,123,130. There are no executives at Supernus Pharmaceuticals Inc getting paid more.
How old is Jack Khattar?
Jack Khattar is 58, he's been the President, Chief Executive Officer, Secretary oraz Director of Supernus Pharmaceuticals Inc since 2005. There are 12 older and 4 younger executives at Supernus Pharmaceuticals Inc. The oldest executive at Supernus Pharmaceuticals Inc is John Siebert, 80, who is the Independent Director.
What's Jack Khattar's mailing address?
Jack's mailing address filed with the SEC is C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850.
Insiders trading at Supernus Pharmaceuticals Inc
Over the last 13 years, insiders at Supernus Pharmaceuticals Inc have traded over $37,265,765 worth of Supernus Pharmaceuticals Inc stock and bought 16,600,700 units worth $83,216,588 . The most active insiders traders include Forest Baskett, Scott D Sandell oraz Peter J Barris. On average, Supernus Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $4,263,834. The most recent stock trade was executed by Jack A. Khattar on 3 September 2024, trading 21,000 units of SUPN stock currently worth $652,680.
What does Supernus Pharmaceuticals Inc do?
pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
What does Supernus Pharmaceuticals Inc's logo look like?
Complete history of Mr. Khattar stock trades at Supernus Pharmaceuticals Inc i scPharmaceuticals Inc
Supernus Pharmaceuticals Inc executives and stock owners
Supernus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Jack Khattar,
President, Chief Executive Officer, Secretary, Director -
Jack A. Khattar,
Founder, Pres, CEO, Sec. & Director -
Stefan Schwabe,
Executive Vice President - Research and Development, Chief Medical Officer -
Padmanabh Bhatt,
Senior Vice President - Intellectual Property, Chief Scientific Officer -
Tami Martin,
Senior Vice President - Regulatory Affairs -
Dr. Padmanabh P. Bhatt,
Chief Scientific Officer & Sr. VP of Intellectual Property -
Tami T. Martin,
Sr. VP of Regulatory Affairs -
Charles Newhall,
Independent Chairman of the Board -
Frederick Hudson,
Independent Director -
John Siebert,
Independent Director -
Georges Gemayel,
Independent Director -
Carrolee Barlow,
Independent Director -
Frank Mottola,
Senior Vice President, Quality, GMP Operations and Information Technology -
James Kelly,
Chief Financial Officer, Executive Vice President -
Jeff Bozick,
Sr. VP of Supply Chain -
Frank Mottola,
Sr. VP of Quality, GMP Operations & Information Technology -
Kevin T. Anderson,
Compliance Officer -
Timothy C. Dec,
Sr. VP & CFO -
Dr. Jonathan Rubin,
Sr. VP & Chief Medical Officer -
Dr. Bryan A. Roecklein,
VP of Corp. Devel. -
Taylor Raiford,
VP of Sales -
Dr. Todd Horich M.B.A., Ph.D.,
VP of Marketing -
William A. Nuerge,
Director -
M James Barrett,
Director -
Victor Vaughn,
Sr. VP of Sales -
Krishna Kittu Kolluri,
10% owner -
Advisors Llcisaly Samuel Do...,
-
Partners 11 Lp Nea,
10% owner -
Forest Baskett,
10% owner -
Michael Bigham,
Director -
Peter J Barris,
10% owner -
Enterprise Associates 11 Lp...,
10% owner -
Scott D Sandell,
10% owner -
Jones W. Bryan,
VP of Business Development -
Management Ltd Abingworth,
10% owner -
Advisors Llcorbimed Capital...,
-
Michael B Sheffery,
Director -
Gregory S Patrick,
Sr. VP Chief Financial Officer -
Jonathan Rubin,
SVP, Chief Medical Officer -
Timothy C Dec,
Senior Vice-President & CFO -
Bethany Sensenig,
Director